Genmab — November 2016
-
Kender dem ikke. Fik den via vores Facebookgruppe.
-
Fra Zacks: Genmab A/S (GNMSF - Free Report) is a biotech company that develops antibody therapeutics for the treatment of cancer internationally including the U.S. The company has a Zacks Rank #2 and a VGM Score of ‘B’. The Zacks Consensus Estimate for its current year earnings surged 109.8% over the last 60 days. The company’s expected growth rate for the next year is a whopping 224.3%.
-
Zacks Investment Research: Stock Research, Analysis, & Recommendations
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. Gain free stock research access to stock picks, stock screeners, stock reports, portfolio trackers and more.
Zacks Investment Research (www.zacks.com)
-
-
ZACH duer slet ikke, spild af tid og penge
-
Gæt en gang Helge ,, i pengetanken ,, tænk hvis en andefarmer fik fat i mig idag
-

-
Danske forsætter bare med at hælde ud.
-
Vil tro at alt hvad der kan krybe og gå af store amerikanske finanshuse og banker er tilstede.
-
køber ind for hver 10 kr ned, sidste køb 1224
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind